Cazanat 40 mg contains Cabozantinib, an oral multi-kinase inhibitor designed to target multiple pathways that cancers use to grow, spread, and develop blood supply.
It is primarily used in certain kidney, liver, and thyroid cancers that are advanced or metastatic.
Taken once daily by mouth, Cazanat allows patients to continue treatment at home, with regular medical monitoring.

Mechanism of Action

Cabozantinib works by blocking several important receptor tyrosine kinases, including:

• VEGFR (vascular endothelial growth factor receptor) – reducing blood vessel formation (angiogenesis) that feeds tumours.

• MET and AXL receptors – which are often involved in tumour invasiveness and spread (metastasis).

• It also inhibits RET, important in certain thyroid cancers

  Uses / Indications

  Cazanat is used for the treatment of:

  • Advanced renal cell carcinoma (kidney cancer), either alone or after progression on other treatments.

  • Hepatocellular carcinoma (liver cancer), after sorafenib failure.

  • Medullary thyroid carcinoma, especially when disease is progressive and unresectable.

    Adverse Effects

    Because cabozantinib blocks pathways involved not only in tumours but also in normal tissues (like blood vessels and gastrointestinal lining), side effects are relatively common and need careful monitoring.

    Common side effects include:

    • Diarrhoea, nausea, loss of appetite.

    • Fatigue, weight loss.

    • Hand-foot syndrome (redness, swelling, pain of palms and soles).

    • High blood pressure (hypertension).